Tumor Biodistribution
Tumor Biodistribution - Related Videos
13:29
Biodistribution of Nano-drug Carriers: Applications of SEM
0 Views •
2023
Source: Peiman Shahbeigi-Roodposhti and Sina Shahbazmohamadi, Biomedical Engineering Department, University of Connecticut, Storrs, Connecticut Nanoparticles have been increasingly used research towards targeted drug delivery and controlled drug release. While most of these particles have been developed as polymeric or liposomal particles because of their biocompatibility, there is a trend in current research toward the use of metallic and magnetic nanoparticles. These metallic nanoparticles...
06:15
An In Vivo Immunofluorescence Localization Method to Study Antibody Biodistribution
0 Views •
2025
This video demonstrates an in vivo immunofluorescence localization (IVIL) technique to study the biodistribution of tumor-targeting antibodies in a murine model of breast cancer. Upon the intravenous injection of a tumor-specific antibody in the mouse, the tumor is surgically isolated, and the localization of the antibody within the tumor tissue is confirmed via ex vivo immunostaining.
14:04
Viral Nanoparticles for In vivo Tumor Imaging
0 Views •
Cited by 45 •
2012
Plant viral nanoparticles (VNPs) are promising platforms for applications in biomedicine. Here, we describe the procedures for plant VNP propagation, purification, characterization, and bioconjugation. Finally, we show the application of VNPs for tumor homing and imaging using a mouse xenograft model and fluorescence imaging.
13:35
Acute and Chronic Models of Hyperglycemia in Zebrafish: A Method to Assess the Impact of Hyperglycemia on Neurogenesis and the Biodistribution of Radiolabeled Molecules
0 Views •
Cited by 25 •
2017
This work describes methods to establish acute and chronic hyperglycemia models in zebrafish. The aim is to investigate the impact of hyperglycemia on physiological processes, such as constitutive and injury-induced neurogenesis. The work also highlights the use of zebrafish to follow radiolabeled molecules (here, [18F]-FDG) using PET/CT.
08:53
In Vivo Immunofluorescence Localization for Assessment of Therapeutic and Diagnostic Antibody Biodistribution in Cancer Research
0 Views •
Cited by 1 •
2019
The in vivo immunofluorescence localization (IVIL) method can be used to examine in vivo biodistribution of antibodies and antibody conjugates for oncological purposes in living organisms using a combination of in vivo tumor targeting and ex vivo immunostaining methods.
FAQs
Blood flow determines how much of an administered agent reaches tumor vessels, while vascular permeability influences whether it can leave those vessels and enter tumor tissue. These factors help explain why exposure may vary among tumors and between tumor regions. Measuring their effects can reveal delivery barriers that influence treatment distribution and interpretation of therapeutic exposure.
Particle size and surface charge influence how an agent moves through the tumor environment and how effectively it reaches or remains within tumor tissue. Their effects occur alongside vascular permeability and interstitial fluid pressure, so changing one property may alter overall localization. Researchers can therefore compare delivery systems by examining how these characteristics affect tumor accumulation and clearance.
Receptor-mediated binding can increase an agent’s association with cells or structures in tumor tissue, affecting both localization and retention. Its contribution must be considered together with transport through tumor vessels and the interstitial space. Comparing binding-related uptake with distribution in healthy organs helps researchers assess whether a targeted approach improves tumor exposure without increasing unwanted tissue accumulation.
Studies commonly combine imaging, tissue sampling, and quantitative assays to determine where an agent is located and how much is present. Investigators can compare measured tumor accumulation with uptake in healthy organs, producing evidence about localization, systemic distribution, and potential safety concerns. Using more than one measurement approach can provide complementary information about exposure and tissue-specific uptake.
Tumor biodistribution is evaluated to determine whether a drug, imaging agent, nanoparticle, or therapeutic cell reaches the intended tissue and achieves relevant exposure. These data support comparisons among delivery systems, identify distribution barriers, and inform decisions about further development. Uptake in healthy organs is also examined because distribution outside the tumor may indicate potential toxicity.
Distribution measurements can show whether a treatment reaches tumor tissue, penetrates its microenvironment, and remains localized or clears. That information helps connect delivery behavior with treatment efficacy and safety. In precision medicine, these findings may identify why a targeted system performs differently across tumors and guide efforts to optimize delivery for the observed biological barriers.